Eli Lilly and Company Research Report - FY2024 Q2

FY2024 Q2: Manufacturing Scale-Up Fuels Incretin Momentum, Prompting $3 Billion Full-Year Revenue Guidance Increase

Sign in required

Sign in or create an account to continue to this document.

Pic
dbot